azvudine   Click here for help

GtoPdb Ligand ID: 13479

Synonyms: RO-0622
Compound class: Synthetic organic
Comment: Azvudine is a nucleoside analogue that was first identified as an inhibitor of the HIV-1 RNA-dependent RNA polymerase (RdRp) [4]. It has more recently been reported to inhibit RdRp from the SARS-CoV-2 betacoronavirus [5]. The active triphosphate metabolite concentrates in the thymus and peripheral blood mononuclear cells, and oral treatment induces curative mechanisms in preclinical models.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 3
Topological polar surface area 120.74
Molecular weight 286.22
XLogP -1.43
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CN([C@H]2[C@H]([C@@H]([C@](CO)(N=[N+]=[N-])O2)O)F)C(=O)N=C1N
Isomeric SMILES C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@](O2)(CO)N=[N+]=[N-])O)F
InChI InChI=1S/C9H11FN6O4/c10-5-6(18)9(3-17,14-15-12)20-7(5)16-2-1-4(11)13-8(16)19/h1-2,5-7,17-18H,3H2,(H2,11,13,19)/t5-,6-,7+,9+/m0/s1
InChI Key KTOLOIKYVCHRJW-XZMZPDFPSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Bolinger AA, Li J, Xie X, Li H, Zhou J. (2024)
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery.
Expert Opin Drug Discov, 19 (9): 1023-1041. [PMID:39078037]
2. da Silva RM, Gebe Abreu Cabral P, de Souza SB, Arruda RF, Cabral SPF, de Assis ALEM, Martins YPM, Tavares CAA, Viana Junior AB, Chang J et al.. (2023)
Serial viral load analysis by DDPCR to evaluate FNC efficacy and safety in the treatment of mild cases of COVID-19.
Front Med (Lausanne), 10: 1143485. [PMID:37007788]
3. de Souza SB, Cabral PGA, da Silva RM, Arruda RF, Cabral SPF, de Assis ALEM, Viana Junior AB, Degrave WMS, Moreira ADS, Silva CG et al.. (2023)
Phase III, randomized, double-blind, placebo-controlled clinical study: a study on the safety and clinical efficacy of AZVUDINE in moderate COVID-19 patients.
Front Med (Lausanne), 10: 1215916. [PMID:37928473]
4. Sun L, Peng Y, Yu W, Zhang Y, Liang L, Song C, Hou J, Qiao Y, Wang Q, Chen J et al.. (2020)
Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention.
J Med Chem, 63 (15): 8554-8566. [PMID:32678592]
5. Zhang JL, Li YH, Wang LL, Liu HQ, Lu SY, Liu Y, Li K, Liu B, Li SY, Shao FM et al.. (2021)
Azvudine is a thymus-homing anti-SARS-CoV-2 drug effective in treating COVID-19 patients.
Signal Transduct Target Ther, 6 (1): 414. [PMID:34873151]